skip to Main Content

Centers for Medicare & Medicaid Services (CMS) January 28th 2018 Local Coverage Determination (LCD) Updates

Centers for Medicare & Medicaid Services (CMS) Local Coverage Determination (LCD) Updates »

January 28th 2018 LCD Updates:

  • DL37600 Administrative Multianalyte Assays with Algorithmic Analyses (MAAA) and Proprietary Laboratory Analyses (PLA) Services
  • A53387 Aflibercept (Eylea) Coding and Billing Guidelines
  • A53387 Aflibercept (Eylea) Coding and Billing Guidelines
  • L36408 Allergy Immunotherapy
  • A52371 Bortezomib – Related to LCD L33394
  • L33392 Category III CPT® Codes
  • L34093 Chemotherapy and Biologicals
  • L34585 Chiropractic Services
  • A55052 Coding Radiopharmaceutical Agents
  • A52399 Denosumab (Prolia ™, Xgeva ™) – Related to LCD L33394
  • A54176 Drug Administration Coding
  • L34303 (retired) Drugs and Biologicals: Bevacizumab (AVASTIN®)
  • L34304 (retired) Drugs and Biologicals: Gemcitabine Hydrochloride (Gemzar ®)
  • L34305 (retired) Drugs and Biologicals: Oxaliplatin (Eloxatin ®)
  • L34306 (retired) Drugs and Biologicals: Rituximab (Rituxan ®)
  • L34315 Electrocardiograms
  • L37283 Electrocardiograms
  • DL37697 Emergency and Non-Emergency Ground Ambulance Services
  • DL37606 Genomic Sequence Analysis Panels in the Treatment of Hematolymphoid Diseases
  • L34563 Home Health Speech-Language Pathology
  • L34699 Human Granulocyte/Macrophage Colony Stimulating Factors
  • L34307 (retired) Medicine: Dysphagia/Swallowing Therapy
  • L34308 (retired) Medicine: Occupational Therapy – Outpatient
  • L34309 (retired) Medicine: Partial Hospitalization Programs
  • L34310 (retired) Medicine: Physical Therapy – Outpatient
  • L34311 (retired) Medicine: Speech Language Pathology – Outpatient
  • L37578 Micro-Invasive Glaucoma Surgery (MIGS)
  • L37578 Micro-Invasive Glaucoma Surgery (MIGS)
  • A55145 MolDX: BCKDHB Gene Test Coding and Billing Guidelines
  • A55161 MolDX: FDA-Approved BRAF Tests
  • A55193 MolDX: FDA-Approved EGFR Tests
  • A54421 (retired) MolDX: FDA-Approved EGFR Tests Billing and Coding Guidelines
  • A54423 (retired) MolDX: FDA-Approved EGFR Tests Billing and Coding Guidelines
  • A54497 (retired) MolDX: FDA-Approved KRAS Tests
  • A54501 (retired) MolDX: FDA-Approved KRAS Tests
  • A55162 MolDX: FDA-Approved KRAS Tests
  • L36400 MolDX: Genetic Testing for Hypercoagulability/Thrombophilia (Factor V Leiden, Factor II Prothrombin, and MTHFR)
  • L36789 MolDX: Genomic Health™ Oncotype DX® Prostate Cancer Assay
  • L36807 MolDX: Molecular Diagnostic Tests (MDT)
  • L37226 MolDX: Prolaris™ Prostate Cancer Genomic Assay for Men with Favorable Intermediate Risk Disease
  • L37539 MolDX: Prometheus IBD sgi Diagnostic Policy
  • A55822 MolDX: ThermoFisher Oncomine Dx Target Test For Non-Small Cell Lung Cancer, Coding and Billing Guidelines
  • A55484 MolDX: TP53 Gene Test Billing and Coding Guidelines
  • A55487 MolDX: TP53 Gene Test Billing and Coding Guidelines
  • A55222 MolDX: UGT1A1 Gene Analysis Coding and Billing Guidelines
  • A55232 MolDX: VEGFR2 Tests Coding and Billing Guidelines
  • L35000 Molecular Pathology Procedures
  • DL35000 Molecular Pathology Procedures
  • A54862 Nivolumab – Related to LCD L33394
  • A52480 Oral Antiemetic Drugs (Replacement for Intravenous Antiemetics) – Policy Article
  • L34106 Percutaneous Vertebral Augmentation
  • L34228 Percutaneous Vertebral Augmentation
  • L34228 Percutaneous Vertebral Augmentation
  • L34646 Psychological and Neuropsychological Testing
  • A55879 Response to Comments: MolDX: Prometheus IBD sgi Diagnostic Policy (L37539)
  • A55884 Response to Comments: Treatment of varicose veins of the lower extremity, L33762
  • A53018 Surveillance of Implantable or Wearable Cardioverter Defibrillators (ICDs): Office, Hospital, Web, or Non-Web Based – Medical Policy Article
  • L34588 Trigger Points, Local Injections
  • L34592 Vertebroplasty (Percutaneous) and Vertebral Augmentation including cavity creation
  • L36831 Visual Electrophysiology Testing


Centers for Medicare & Medicaid Services (CMS) Local Coverage Determination (LCD) Updates »


Policy Alerts monitors Commercial and Medicare medical policies for changes. While Payers typically update medical policies annually, there are many reasons why a Payer might review or update a policy. When reviews occur out of cycle, they may go unnoticed. Policy Alerts keeps you informed of upcoming and unexpected coverage changes affecting your product. Quickly understanding the changes Payers make can help you adjust reimbursement strategies impacting your business.

Policy Alerts continuously monitors Commercial and Medicare Payer coverage information to keep you up-to-date on Payer decisions in real-time. Whenever changes occur, email notifications containing a summary of those changes are delivered to your inbox. Clients can access detailed coverage reports and medical policies on the interactive Dashboard portal. Save time and keep focused on the important Payer medical policy reviews and coverage decisions affecting your product!

Policy Alerts takes a client-focused hands-on approach and works hard to provide our customers with helpful insights and actionable analytics over raw data. We understand what our clients need and we are dedicated to making sure we provide timely, accurate and always up-to-date reports that can be used to implement and support a successful reimbursement strategy.

Health economic and reimbursement information provided by Policy Alerts is gathered from third-party sources and is subject to change without notice as a result of complex and frequently changing laws, regulations, rules and policies. This information is presented for illustrative purposes only and does not constitute reimbursement or legal advice.

Back To Top